# Evaluation of ARI-3037MO, to Suppress LDL Cholesterol in Patients With Dyslipidemia

Study · id `cardio:ct-nct02532218` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02532218](<https://clinicaltrials.gov/study/NCT02532218>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02532218

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 176 participants.

## Technical summary

Registry record NCT02532218. Randomized; quadruple masking; primary purpose treatment. Start 2015-08 (registry gives no type); primary completion 2016-09 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 176 participants (planned count; ClinicalTrials.gov record NCT02532218, source copy `cardio:ctgov-nct02532218-2016-08-08`, retrieved 2026-10-31)
- Start date: 2015-08 (registry gives no type) (ClinicalTrials.gov record NCT02532218, source copy `cardio:ctgov-nct02532218-2016-08-08`, retrieved 2026-10-31)
- Primary completion: 2016-09 (anticipated) (ClinicalTrials.gov record NCT02532218, source copy `cardio:ctgov-nct02532218-2016-08-08`, retrieved 2026-10-31)
- Completion: 2016-12 (anticipated) (ClinicalTrials.gov record NCT02532218, source copy `cardio:ctgov-nct02532218-2016-08-08`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT02532218, source copy `cardio:ctgov-nct02532218-2016-08-08`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02532218-2016-08-08`, retrieved 2026-10-31)

## The registry's words

- Brief title: Evaluation of ARI-3037MO, to Suppress LDL Cholesterol in Patients With Dyslipidemia
- Acronym: REASCEND
- Condition: Hyperlipidemia
- Intervention (Drug): ARI-3037MO
- Lead sponsor: Arisaph Pharmaceuticals Inc
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)

## Provenance

Content hash: 0f58cd444749accbc8c80665ee5bc14ced2f09459aa569ac37980f6b382871c8
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
